Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment. Most incidence and prevalence studies for UC show males and ...

Ulcerative colitis is a chronic relapsing and remitting inflammatory disorder that can generally be managed successfully with maintenance oral medications. However, approximately 15% of patients ...

Ulcerative colitis (UC) can cause severe symptoms which can adversely affect a person’s quality of life and ability to work. As such, UC may qualify as a disability. Some potential benefits ...

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology.

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly growing into the established UC market as this IL-23 inhibitor ...